Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty

Not Applicable

• Conditions: Arthroplasties, Knee Replacement; Revision Arthroplasty
• Interventions: Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC; Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision; Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS

• Registration Number: NCT06203756
• Lead Sponsor: Corin

Brief Summary

This is a post-market multicentre study that has been implemented to confirm safety and performance of cemented CR/UC and PS Apex Knee implants in primary or revision Robotic Assisted Total Knee Arthroplasty up to 10-year follow up.

Detailed Description

This study has been implemented to confirm safety and performance of cemented CR/UC and PS Apex Knee implants in primary or revision RA-TKA up to 10-year follow up.

Prospective data will be collected for this Post Market Clinical Follow up (PMCF) study and the data will be fed into the Post-Market Surveillance (PMS) and Clinical Evaluation processes of the devices under assessment on annual basis and support presentations at orthopaedic congresses and/or peer-reviewed publication(s).

Participants will be selected for recruitment into the study from the general population of participants requiring a primary or revision knee-arthroplasty and considered suitable to receive the Apex Knee System.

Study Timeline

• Study Start: 2017-11-09
• Study First Submitted: 2023-12-11
• Study First Submitted QC: 2024-01-02
• Study First Posted: 2024-01-12
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-15
• Last Update Posted: 2025-05-20
• Primary Completion: 2029-01-01
• Study Completion: 2040-04-01

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 713

Inclusion Criteria

1. Patient must be a candidate for a primary or revision total knee arthroplasty
2. Patient is able and willing to sign the informed consent and follow study procedures
3. Patient's joint must be anatomically and functionally suited to receive the selected implant and accommodate use of the robotic assistance

Exclusion Criteria

1. Patient has a BMI >45.
2. Significant neurological or musculoskeletal disorders or disease that may interfere with total knee arthroplasty survival, adversely affect gait or weight bearing, (i.e. Paget's disease, Charcot's disease, muscular dystrophy, multiple sclerosis).
3. The presence of highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, HIV, etc.).
4. Presence of known active metastatic or neoplastic disease.
5. Cancer patients unless they have received curative treatment and have no evidence of recurrence for 5 years.
6. Patient has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease).
7. Patient has an active infection or joint sepsis.
8. Patient has muscular, neurological or vascular deficiencies which compromise the affected extremity (i.e., Parkinson's Disease, Multiple Sclerosis, and Charcot joints).
9. Patients with allergies or suspected sensitivity to any patient-contacting component of the implant to be used in the study Has known sensitivity to implants or the materials in the device including but not limited to: Ti, Al, V, Co, Cr, Mo, Ni and Si3N4.).
10. Patients who are currently on medical leave from their employment due to Worker's Compensation.
11. Patients who are at high risk for poor healing or confounding outcomes or at excessive risk for surgery (e.g., clinically significant/being actively treated for renal, hepatic, cardiac, hematologic, or neurologic disease or poorly controlled diabetes (HbA1c > 8 mg/dL) or previous history of joint infection).
12. Patients who are known drug or alcohol abusers or with psychological disorders as defined by DSM V that could affect follow-up care or treatment outcomes.
13. Patients who are currently involved in another clinical study with an investigational device.
14. Patients with current litigation pending related to medical treatment of any sort.
15. Patients, who, in the opinion of the investigator, will not be able to complete the study per the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Femur First, Non Sensor-assisted	Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC	Standard robotic surgery cohort with a femur first workflow. Sensor used only to measure final balance achieved with surgeon blinded to measurements.
Tibia First, Sensor-assisted	Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS	Sensor-assisted robotic surgery cohort with a tibia first workflow
Revision Total Knee Arthroplasty	Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision	Sensor-assisted robotic surgery cohort with a tibia first workflow. Revision Total Knee Arthroplasty components.
Tibia First, Non Sensor-assisted	Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC	Standard robotic surgery cohort with a tibia first workflow. Sensor used only to measure final balance achieved with surgeon blinded to measurements.
Femur First, Sensor-assisted	Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC	Sensor-assisted robotic surgery cohort with a femur first workflow
Tibia First, Sensor-assisted	Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC	Sensor-assisted robotic surgery cohort with a tibia first workflow

Primary Outcome Measures

Name	Time	Method
Survivorship	10 Years	Frequency of device and implant related adverse events and revision surgery to be recorded.

Secondary Outcome Measures

Name	Time	Method
Change in UCLA from baseline to 10 years after surgery	from enrolment to 10 years	Evaluate impact of participants knee surgery, comparing post-operative Knee Injury and University of California Los Angeles (UCLA) activity Scale and measured the participants usual level of activity; UCLA ranges from 0 - 10, in which the higher the score the greater the activity
Change in Promis-10 from baseline to 10 years after surgery	from enrolment to 10 years	Evaluate impact of participants knee surgery, comparing post-operative Knee Injury and Patient-Reported Outcomes Measurement Information System (PROMIS) and measures the participants physical, mental, and social health.; PROMIS-10 ranges from 1 - 67, in which 67 is best.
Change in KOOS from baseline to 10 years after surgery	from enrolment to 10 years	Evaluate impact of participants knee surgery, comparing post-operative Knee Injury and Osteoarthritis Outcome Score (KOOS) Scores and participants opinion about their knee; KOOS ranges from 0 - 100, in which 100 is best.

Trial Locations

Locations (6)

Flagstaff Bone and Joint; 🇺🇸 Flagstaff, Arizona, United States

Orthopaedics New England; 🇺🇸 Middlebury, Connecticut, United States

DeClaire LaMacchia Orthopaedic Institute; 🇺🇸 Rochester,, Michigan, United States

Nyu Langone-Long Island; 🇺🇸 Garden City, New York, United States

Oklahoma Sports and Orthopedics Institute; 🇺🇸 Oklahoma City, Oklahoma, United States

Gundersen Health System; 🇺🇸 La Crosse, Wisconsin, United States